Abbott and Google Partner to Bring AI-Powered Glucose Coaching to Consumers

Abbott and Google announced a multi-year partnership on August 11, 2026, to connect Abbott's Lingo continuous glucose monitor (CGM) with Google Health. The deal lets users view metabolic data in the Google Health app and receive AI-driven recommendations through a feature called Google Health Coach (Engadget).

The Lingo device is a small wearable sensor that tracks blood sugar levels throughout the day and night, without the finger-prick testing that older glucose monitors required. Abbott launched it over-the-counter in the U.S. in September 2024 at $49 for two weeks and $89 for four weeks. It is intended for adults who do not use insulin — meaning people interested in general metabolic health rather than those managing insulin-dependent diabetes (Reuters). Abbott received FDA clearance for two OTC CGM devices in June 2024. The company positioned Lingo for consumers seeking a better understanding of their health, while its Libre Rio device targets adults with type 2 diabetes who do not need insulin (Reuters).

Under the partnership, a Lingo user's glucose data flows into Google Health, where it can be shared with Google Health Coach — an AI system that generates personalized recommendations based on the individual's data (Engadget). Think of it as a feedback loop: the sensor collects readings, the app displays them, and the AI model translates patterns into practical suggestions about meals and activity. Google's official blog describes the goal as providing more holistic views of metabolic and women's health (Google blog).

Abbott and Google will also conduct one of the largest real-world metabolic health studies to date as part of the deal. The study will integrate continuous glucose data, wearable sensor data, laboratory results, and survey responses into a single analytical pipeline (Engadget). The scale of combined datasets is what makes the study notable — glucose streams from Lingo sensors, biometric inputs from wearables, structured lab values, and self-reported survey data, all feeding into one system.

Abbott has been building toward AI-augmented glucose management on its own platform as well. The company's Libre Assist feature, available in the FreeStyle Libre app, uses food photos and AI analysis to predict a meal's potential glucose impact before eating (Abbott). That feature predates the Google partnership but points in the same direction: using machine learning to translate raw glucose data into actionable, in-the-moment guidance.

The two companies have prior collaborative groundwork. In Singapore, as part of Google's chronic-disease efforts, Abbott and Health2Sync built a 12-week digital health program designed to help people manage glucose through lifestyle changes (Google blog). The new partnership extends that kind of integrated approach to a broader consumer audience.

The partnership arrives roughly nine months after Abbott issued a U.S. device correction in November 2025 for some of its glucose monitors over faulty readings, advising users to stop using affected sensors and rely on a blood glucose meter for treatment decisions (Reuters). The correction applied to a specific set of sensors, not the Lingo product line broadly, but it is a reminder that sensor accuracy remains a live concern as CGM data increasingly feeds into AI-driven health recommendations. If an AI coach is basing meal or activity suggestions on glucose readings, the accuracy of those readings is the foundation for everything built on top.

The broader context here involves regulatory and safety questions that the announcement does not fully address. Lingo is an OTC device for non-insulin users, which places it outside the clinical oversight that accompanies prescription CGM use for insulin-dependent diabetes management. The Google Health Coach recommendations are AI-generated, and the partnership does not detail clinical validation pathways for those recommendations. The architecture is familiar to anyone who works with machine learning: sensor data feeds a model, the model produces guidance, the guidance reaches a consumer through an app. The question is whether that guidance loop has been validated against clinical outcomes — and neither Abbott nor Google has publicly specified how that validation works within this partnership.

The real-world metabolic health study may serve as one such validation mechanism, though its design, duration, and endpoints have not been detailed in the announcement materials. If the study is structured to measure outcomes rather than simply collect data, it could establish an evidence base for AI-mediated glucose coaching that is currently thin.

What this enables is straightforward in concept: a consumer wearing a Lingo sensor sees glucose trends in Google Health, receives AI-generated suggestions about meals and activity, and participates in a study that aggregates their data into a population-scale metabolic dataset. Whether that loop produces better health outcomes than the sensor alone is the empirical question, and it is the right one to ask. The partnership brings together two companies with complementary capabilities: Abbott's sensor hardware and clinical heritage in glucose monitoring, and Google's data infrastructure, AI models, and consumer-facing health platform. The integration of continuous glucose data with wearable and lab data at scale is something neither company could readily achieve alone.